NEW YORK (GenomeWeb) – CombiMatrix announced today that it has selected Cryoport as its cryogenic logistics partner for the distribution of its CombiPGS preimplantantion genetic screening test for women undergoing in vitro fertilization.
According to CombiMatrix, Cryport handles the shipment of frozen eggs, embryos, and sperm for the reproductive medicine market throughout the US and in more than 80 countries worldwide.
"The sensitivity of our tests requires across-the-board reliability, which is also a strict mandate for all of our partners," CombiMatrix President and CEO Mark McDonough said in a statement. "Cryoport's validated cryogenic logistics solutions give us great confidence that our CombiPGS service will have dependable access to the global market."
Financial terms of the arrangement were not disclosed.